- Conditions
- Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Malignant Peripheral Nerve Sheath Tumor, Locally Advanced Myxofibrosarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Angiosarcoma, Metastatic Epithelioid Sarcoma, Metastatic Fibrosarcoma, Metastatic Liposarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Myxofibrosarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Undifferentiated (Embryonal) Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Malignant Peripheral Nerve Sheath Tumor, Unresectable Soft Tissue Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
- Interventions
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2473–2496
of 10,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Congenital Bleeding Disorder, Haemophilia A
- Interventions
- turoctocog alfa
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Up to 11 Years · Male only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Orange, California • Torrance, California + 15 more
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- Pomalidomide
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 11
- States / cities
- San Diego, California • San Francisco, California • Gainesville, Florida + 8 more
- Conditions
- Congestive Heart Failure, Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis
- Interventions
- Respiratory Sensor measurements
- Device
- Lead sponsor
- Institute of Bioengineering and Bioimaging (IBB)
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia, Inborn Errors of Metabolism, Bone Marrow Failure Syndromes, Immunodeficiencies, Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome
- Interventions
- Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)
- Biological
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Type 2 Diabetes
- Interventions
- Exercise program, Ascorbic Acid (Vitamin C)
- Behavioral · Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 30 Years to 55 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Sickle Cell Disease, Genetic Disease, Hematologic Diseases, Anemia, Sickle Cell
- Interventions
- Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Oakland, California • Augusta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Lax Skin
- Interventions
- Sofwave
- Device
- Lead sponsor
- Sofwave Medical LTD
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- La Mesa, California • Durham, North Carolina
- Conditions
- Hereditary Sensory and Autonomic Neuropathy Type I
- Interventions
- L-serine, placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Worcester, Massachusetts
- Conditions
- Genetic Skin Disease, Keratosis Follicularis, Lamellar Ichthyosis
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1992 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor, Interstitial Cystitis, Congenital Abnormalities, End Stage Renal Disease, Renal Tumor, Kidney Injury
- Interventions
- RAS Prostatectomy, RAS Cystectomy, RAS Nephrectomy
- Device
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 6
- States / cities
- Duarte, California • Chicago, Illinois • New York, New York + 3 more
- Conditions
- Amyloidosis, Hereditary
- Interventions
- Registry
- Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Urothelial Cancer
- Interventions
- Bintrafusp alfa (M7824)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Vascular Anomaly
- Interventions
- Topical Sirolimus
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 36 Months to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Orlando, Florida
- Conditions
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
- Interventions
- Acoramidis (AG10) oral tablet
- Drug
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • St Louis, Missouri • Philadelphia, Pennsylvania
- Conditions
- Sickle Cell Disease
- Interventions
- AG-348
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atopic Dermatitis
- Interventions
- EpiCeram Skin Barrier Emulsion, Experimental Product 1% Colloidal Oatmeal Balm
- Device · Drug
- Lead sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Colorado Springs, Colorado • Richardson, Texas
- Conditions
- Lennox-Gastaut Syndrome
- Interventions
- Rufinamide, Any other approved Antiepileptic Drug
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 1 Year to 3 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 22
- States / cities
- San Diego, California • Aurora, Colorado • Washington D.C., District of Columbia + 19 more
- Conditions
- Hand Deformities
- Interventions
- BION stimulation
- Device
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Downey, California
- Conditions
- Sickle Cell Disease
- Interventions
- Collaborative Care Model, Promoting Resilience in Stress Management
- Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 8 Years to 25 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Congenital Heart Defects, Blood Platelet Disorders
- Interventions
- Clopidogrel (SR25990)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- Up to 24 Months
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Neurofibromatosis
- Interventions
- Questionnaires
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Arteriovenous Fistula Stenosis, Arteriovenous Fistula Occlusion, Arteriovenous Fistula, Fistula
- Interventions
- IN.PACT AV DCB, Standard Balloon Angioplasty
- Device
- Lead sponsor
- Medtronic Endovascular
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Sacramento, California + 18 more
- Conditions
- Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, Hemophilia A, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, Hematologic Diseases, Hemorrhagic Disorders, Factor VIII Deficiency
- Interventions
- Standard of Care FVIII Replacement therapy
- Drug
- Lead sponsor
- Spark Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 25 participants
- Timeline
- 2019 – 2023
- U.S. locations
- 6
- States / cities
- San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 3 more